Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and the bet did not pay off.
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test